Sarah Kratina, Christopher Lo, Carol Strike, Robert Schwartz, Brian Rush
{"title":"用迷幻药缓解与危及生命的诊断相关的心理痛苦:加拿大政策讨论的时机已到。","authors":"Sarah Kratina, Christopher Lo, Carol Strike, Robert Schwartz, Brian Rush","doi":"10.12927/hcpol.2023.27048","DOIUrl":null,"url":null,"abstract":"<p><p>In Canada, the conversation to enable access to therapeutic psychedelics is under way. With recent federal initiatives, Canadians can request access to psychedelic-assisted therapies (PATs) to alleviate enduring and intolerable psychological suffering (EIPS) associated with life-threatening conditions on a case-by-case basis. The resurgence of past research concerning the therapeutic potential of PATs, promising preliminary results from contemporary clinical trials, public and media interest and the recognition of traditional Indigenous use of psychedelics have facilitated a change in the popular narrative around these stigmatized substances. A lack of access to PATs for treating EIPS, especially at end of life, is a public policy problem worth addressing.</p>","PeriodicalId":39389,"journal":{"name":"Healthcare Policy","volume":"18 4","pages":"134-142"},"PeriodicalIF":0.0000,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10370393/pdf/","citationCount":"0","resultStr":"{\"title\":\"Psychedelics to Relieve Psychological Suffering Associated with a Life-Threatening Diagnosis: Time for a Canadian Policy Discussion.\",\"authors\":\"Sarah Kratina, Christopher Lo, Carol Strike, Robert Schwartz, Brian Rush\",\"doi\":\"10.12927/hcpol.2023.27048\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>In Canada, the conversation to enable access to therapeutic psychedelics is under way. With recent federal initiatives, Canadians can request access to psychedelic-assisted therapies (PATs) to alleviate enduring and intolerable psychological suffering (EIPS) associated with life-threatening conditions on a case-by-case basis. The resurgence of past research concerning the therapeutic potential of PATs, promising preliminary results from contemporary clinical trials, public and media interest and the recognition of traditional Indigenous use of psychedelics have facilitated a change in the popular narrative around these stigmatized substances. A lack of access to PATs for treating EIPS, especially at end of life, is a public policy problem worth addressing.</p>\",\"PeriodicalId\":39389,\"journal\":{\"name\":\"Healthcare Policy\",\"volume\":\"18 4\",\"pages\":\"134-142\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10370393/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Healthcare Policy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.12927/hcpol.2023.27048\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Healthcare Policy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.12927/hcpol.2023.27048","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
摘要
在加拿大,有关允许使用治疗性迷幻药的讨论正在进行之中。根据最近的联邦倡议,加拿大人可以根据具体情况申请使用迷幻辅助疗法(PATs),以减轻与危及生命的疾病相关的持久和难以忍受的心理痛苦(EIPS)。过去有关迷幻辅助疗法治疗潜力的研究再次兴起,当代临床试验取得了令人鼓舞的初步结果,公众和媒体的兴趣以及对土著人使用迷幻药的传统的认可,这些都促进了围绕这些被污名化的物质的流行说法的改变。无法获得 PATs 治疗 EIPS,尤其是在生命末期,是一个值得解决的公共政策问题。
Psychedelics to Relieve Psychological Suffering Associated with a Life-Threatening Diagnosis: Time for a Canadian Policy Discussion.
In Canada, the conversation to enable access to therapeutic psychedelics is under way. With recent federal initiatives, Canadians can request access to psychedelic-assisted therapies (PATs) to alleviate enduring and intolerable psychological suffering (EIPS) associated with life-threatening conditions on a case-by-case basis. The resurgence of past research concerning the therapeutic potential of PATs, promising preliminary results from contemporary clinical trials, public and media interest and the recognition of traditional Indigenous use of psychedelics have facilitated a change in the popular narrative around these stigmatized substances. A lack of access to PATs for treating EIPS, especially at end of life, is a public policy problem worth addressing.